Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia

被引:1
|
作者
Yunivita, Vycke [1 ,2 ]
Gafar, Fajri [1 ,3 ,4 ]
Santoso, Prayudi [5 ,6 ]
Chaidir, Lidya [2 ,7 ]
Soeroto, Arto Y. [5 ,6 ]
Meirina, Triana N. [8 ]
Te Brake, Lindsey [9 ]
Menzies, Dick [3 ,4 ]
Aarnoutse, Rob E. [9 ]
Ruslami, Rovina [1 ,2 ,4 ]
机构
[1] Univ Padjadjaran, Fac Med, Dept Biomed Sci, Div Pharmacol & Therapy, Bandung, Indonesia
[2] Univ Padjadjaran, Res Ctr Care & Control Infect Dis, TB Working Grp, Bandung, Indonesia
[3] Res Inst McGill Univ Hlth Ctr, Ctr Outcomes Res & Evaluat, Resp Epidemiol & Clin Res Unit, 5252 Blvd Maisonneuve Ouest,Off 3D 21, Montreal, PQ H4A 3S5, Canada
[4] McGill Univ, McGill Int TB Ctr, Montreal, PQ, Canada
[5] Univ Padjadjaran, Fac Med, Dept Internal Med, Div Respirol & Crit Care, Bandung, Indonesia
[6] Hasan Sadikin Gen Hosp, Bandung, Indonesia
[7] Univ Padjadjaran, Fac Med, Dept Biomed Sci, Div Microbiol, Bandung, Indonesia
[8] Univ Padjadjaran, Fac Med, Pharmacokinet Lab, Bandung, Indonesia
[9] Radboud Univ Nijmegen Med Ctr, Radboud Inst Med Innovat, Dept Pharm, Nijmegen, Netherlands
关键词
BACTERICIDAL ACTIVITY; CULTURE CONVERSION; TB PATIENTS; DRUGS; PHENOTYPE; GENOTYPE;
D O I
10.1093/jac/dkae057
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background :Pharmacokinetic data on high-dose isoniazid for the treatment of rifampicin-/multidrug-resistant tuberculosis (RR/MDR-TB) are limited. We aimed to describe the pharmacokinetics of high-dose isoniazid, estimate exposure target attainment, identify predictors of exposures, and explore exposure-response relationships in RR/MDR-TB patients. Methods: We performed an observational pharmacokinetic study, with exploratory pharmacokinetic/pharmacodynamic analyses, in Indonesian adults aged 18-65 years treated for pulmonary RR/MDR-TB with standardized regimens containing high-dose isoniazid (10-15 mg/kg/day) for 9-11 months. Intensive pharmacokinetic sampling was performed after >= 2 weeks of treatment. Total plasma drug exposure (AUC(0-24)) and peak concentration (Cmax) were assessed using non-compartmental analyses. AUC(0-24)/MIC ratio of 85 and C-max/MIC ratio of 17.5 were used as exposure targets. Multivariable linear and logistic regression analyses were used to identify predictors of drug exposures and responses, respectively. Results :We consecutively enrolled 40 patients (median age 37.5 years). The geometric mean isoniazid AUC(0-24 )and Cmax were 35.4 h center dot mg/L and 8.5 mg/L, respectively. Lower AUC0-24 and Cmax values were associated (P < 0.05) with non-slow acetylator phenotype, and lower Cmax values were associated with male sex. Of the 26 patients with MIC data, less than 25% achieved the proposed targets for isoniazid AUC(0-24)/MIC (n = 6/26) and C-max/MIC (n = 5/26). Lower isoniazid AUC0-24 values were associated with delayed sputum culture conversion (>2 months of treatment) [adjusted OR 0.18 (95% CI 0.04-0.89)]. Conclusions :Isoniazid exposures below targets were observed in most patients, and certain risk groups for low isoniazid exposures may require dose adjustment. The effect of low isoniazid exposures on delayed culture conversion deserves attention.
引用
收藏
页码:977 / 986
页数:10
相关论文
共 50 条
  • [41] Pharmacokinetic study of high-dose oral rifampicin in critically Ill patients with multidrug-resistant Acinetobacter baumannii infection
    Hossein Karballaei-Mirzahosseini
    Romina Kaveh-Ahangaran
    Bita Shahrami
    Mohammad Reza Rouini
    Atabak Najafi
    Arezoo Ahmadi
    Sima Sadrai
    Amirmahdi Mojtahedzadeh
    Farhad Najmeddin
    Mojtaba Mojtahedzadeh
    DARU Journal of Pharmaceutical Sciences, 2022, 30 : 311 - 322
  • [42] Pharmacokinetic study of high-dose oral rifampicin in critically Ill patients with multidrug-resistant Acinetobacter baumannii infection
    Karballaei-Mirzahosseini, Hossein
    Kaveh-Ahangaran, Romina
    Shahrami, Bita
    Rouini, Mohammad Reza
    Najafi, Atabak
    Ahmadi, Arezoo
    Sadrai, Sima
    Mojtahedzadeh, Amirmahdi
    Najmeddin, Farhad
    Mojtahedzadeh, Mojtaba
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 30 (02) : 311 - 322
  • [43] High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection
    Cynamon, MH
    Zhang, Y
    Harpster, T
    Cheng, S
    DeStefano, MS
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (12) : 2922 - 2924
  • [44] High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis/rifampicin in Ghana
    Boakye-Appiah, Justice K.
    Steinmetz, Alexis R.
    Pupulampu, Peter
    Ofori-Yirenkyi, Stephen
    Tetteh, Ishmael
    Frimpong, Michael
    Oppong, Patrick
    Opare-Sem, Ohene
    Norman, Betty R.
    Stienstra, Ymkje
    van der Werf, Tjip S.
    Wansbrough-Jones, Mark
    Bonsu, Frank
    Obeng-Baah, Joseph
    Phillips, Richard O.
    INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2016, 5 (02) : 226 - 230
  • [45] Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis
    Deshpande, Devyani
    Pasipanodya, Jotam G.
    Mpagama, Stellah G.
    Srivastava, Shashikant
    Bendet, Paula
    Koeuth, Thearith
    Lee, Pooi S.
    Heysell, Scott K.
    Gumbo, Tawanda
    CLINICAL INFECTIOUS DISEASES, 2018, 67 : S317 - S326
  • [47] Should isoniazid and clofazimine be used to treat multidrug-resistant tuberculosis?
    Seung, KJ
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2005, 9 (02) : 231 - 232
  • [48] Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid
    Chirehwa, Maxwell T.
    McIlleron, Helen
    Wiesner, Lubbe
    Affolabi, Dissou
    Bah-Sow, Oumou
    Merle, Corinne
    Denti, Paolo
    N'Diaye, Alimatou
    Mbaye, Ibrahima Marietou
    De Jong, Bouke
    Anagonou, Severin
    Diatema, Salim
    Gomina, Ibrahima Khalil
    Gossa, Severin
    Tanimomo, Blanche
    Bekou, Wilfried
    Galperine, Tatiana
    Furco, Andre
    Diallo, Mouctar
    Bah, Boubacar
    Bah, Falilou
    Barry, Nene
    Barry, Abdourahmane
    Barry, Sadjo
    Barry, Mamadou Telly
    Sylla, Aissatou Bah
    Barry, Alpha Mamadou
    Sarr, Marie
    Ngom, Ndeye Fatou
    Ndiaye, Kine
    Sakho, Diama
    Ngom, Justine
    Ba, Fatoumata
    Seck, Amadou
    Furco, Andre
    Floyd, Sian
    Branson, Keith
    Glynn, Judith
    Phillips, Dany
    Oubaya, Nadia
    Saint-Martin, Caroline
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (01) : 139 - 148
  • [49] Treatment Outcomes in Multidrug-Resistant Tuberculosis
    Guenther, Gunar
    Lange, Christoph
    Alexandru, Sofia
    Altet, Neus
    Avsar, Korkut
    Bang, Didi
    Barbuta, Raisa
    Bothamley, Graham
    Ciobanu, Ana
    Crudu, Valeriu
    Danilovits, Manfred
    Dedicoat, Martin
    Duarte, Raquel
    Gualano, Gina
    Kunst, Heinke
    de Lange, Wiel
    Leimane, Vaira
    Magis-Escurra, Cecile
    McLaughlin, Anne-Marie
    Muylle, Inge
    Polcova, Veronika
    Popa, Christina
    Rumetshofer, Rudolf
    Skrahina, Alena
    Solodovnikova, Varvara
    Spinu, Victor
    Tiberi, Simon
    Viiklepp, Piret
    van Leth, Frank
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (11): : 1103 - +
  • [50] Determination of risk factors for isoniazid monoresistance and multidrug-resistant tuberculosis in treatment failure patients
    Vadwai, Viral
    Shetty, Anjali
    Soman, Rajeev
    Rodrigues, Camilla
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2012, 44 (01) : 48 - 50